Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... , July 22, 2014  The Broad ... million from philanthropist Ted Stanley aimed ... bringing new treatments based on molecular understanding to ... The Stanley commitment – the ... largest for scientific research in general – will ...
    (Date:7/22/2014)... July 22, 2014  United Therapeutics Corporation (NASDAQ: ... will release its second quarter 2014 financial results ... United Therapeutics will host a half-hour ... a.m. Eastern Time.  The teleconference is accessible by ... rebroadcast of the teleconference will be available for ...
    (Date:7/22/2014)... PLAINS, New Jersey , 22. Juli 2014 ... für die Life-Sciences-Industrie, hat die Ernennung von Marcus ... bekanntgegeben. Herr Bergler hat die europäischen kommerziellen ... Lösungen unterstützt. Bevor er sich Qforma anschloss, war ... bei Cegedim Customer Information, als Vertriebsteam-Leiter Deutschland bei ...
    (Date:7/22/2014)... 2014 The next session of ... and will comprise of the increasingly popular ‘Base SAS’ ... is a series of technical hands-on classes for entry-level ... reach the next step in their professional careers. , ... by Jennifer Kang, Senior Statistician at Genentech and former ...
    Breaking Biology Technology:$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3
    ... has been awarded the International Union of Pure and ... Physics. , The award acknowledges Dr Barnard as a ... structures, shapes and crystal structures of materials at the ... Institute of Technology (RMIT) University in 2001 and ...
    ... Amnis Corporation, a manufacturer of advanced cell imaging ... imaging flow cytometer. The new instrument - the ... the speed, sensitivity, and phenotyping abilities of flow cytometry ... The new ImageStreamX greatly expands the capabilities of ...
    ... Biotech Ltd. (Amex: SVA ), a leading provider ... a conference call on Friday, May 15, 2009 at 9:00 ... for the period ended March 31, 2009 and provide an ... dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of ...
    Cached Biology Technology:Big prize for 'small science' physicist 2Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results 2
    (Date:7/21/2014)... from the strength of immune response, rather than with ... attacking the virus, might be a better way to ... of Washington, Seattle. She and her collaborators have now ... the H7N9 influenza, and their work has already led ... virulent strain. The research is published ahead of print ...
    (Date:7/21/2014)... By tracking hybrids between songbird species, investigators have found ... be preventing interbreeding. The research, which is published in ... like GPS, record the position of a bird and ... Compared with their parents, hybrids exhibited increased variability in ... suitable areas, while others used the same routes as ...
    (Date:7/21/2014)... apple orchards, effective management practices rely on ... competitive vegetation under the trees, and supplying ... are further complicated in organic management systems ... need to meet the stringent soil fertility ... National Organic Program. University of Arkansas scientists ...
    Breaking Biology News(10 mins):Potential new flu drugs target immune response, not virus 2Organic apple orchards benefit from green compost applications 2
    ... a potent neurotoxin and a worrisome environmental contaminant, but ... what else is in the water. Researchers at ... of dissolved organic material increases the biological risk of ... mercury source. Mercury is present throughout the ...
    ... & Leuven, Belgium As the most common form ... enormous implications for our ageing society. It is generally ... (A -peptide) protofibrils. Until now, the conditions under which ... the disease remained unknown. VIB researchers have now discovered ...
    ... will change as carbon dioxide increases, affecting food webs along ... Centre press briefing today. Microbes in the ocean produce ... form above the sea, which reflect the suns rays away ... when they get hot so that clouds will cool them ...
    Cached Biology News:Waterborne carbon increases threat of environmental mercury 2Lipids in the brain an important factor for Alzheimer's disease? 2
    Complement factor B (human)...
    ... The AccuSpot automates LC micro-fractionation, ... With the AccuSpot system, LC eluent ... onto target plates, in trace amounts. ... target plates for MALDI-TOF-MS measurements. When ...
    ... LC Sciences provides a unique new tool, ... synthesis serving diverse needs in genomics, proteomics, ... OligoMix is a MIXTURE of a large ... delivered in a single microtube. OligoMix is ...
    ... Capillary Electrophoresis Running Buffer was designed to ... demands of todays sequencing labs. As a ... to the gel-based sequencing community Sigma has ... to meet your buffer needs. Scientists at ...
    Biology Products: